News dal mondo
21
Apr
TGA clarifies therapeutic goods are unaffected by chemical production and import ban
TGA has clarified the impact of Australia’s industrial chemicals standards on medicines, medical devices, and biologicals. Responding to stakeholder queries, TGA said therapeutic goods are not affected by prohibitions imposed under the Industrial Chemicals Environmental Management Standard (IChEMS). The framework prohibits the import, manufacture, and use of specified chemicals in Australia. Certain PFAS chemicals, UV-328, and Dechlorane Plus are among the chemicals covered by IChEMS. TGA said IChEMS does not apply to chemicals used for therapeutic purposes. That limitation of the standard’s scope extends to the primary and secondary packaging of medicines and biologicals, as well as to the primary packaging, instructions for use, and spare parts of medical devices. The agency posted two statements about the exemption of medical devices from the PFAS ban last year. While TGA’s second statement clarified that medicines and biologicals are exempt from the ban, neither notice addressed chemicals other than PFAS. [RAPS]
18
Giu
AIFA Sistema informatico Workflow Officine Materie Prime - Ulteriore Aggiornamento tecnico 18 maggio 2026
Formati files ammessi: PDF editabile o p7m. Scansioni a 200 dpi, anche in bianco e nero, per ottimizzare...
15
Mag
US FDA’s New AI-Informed Inspection Pilot and What It Means for Industry
We have written on this blog about FDA’s modernization agenda from several angles lately—from...
15
Mag
EU Regulators discuss new pharma legislation, AI, and more
A panel of European regulators answered questions during a town panel discussion at RAPS Euro Convergence...
15
Mag
US FDA official details top observations from QMSR inspections
The top observations identified in Form 483 reports from inspections conducted under the recently implemented...
le ultime news
08 Mag
Min. Salute Gemmato: “Testo unico farmaceutico entro dicembre 2026”
08 Mag
Precursori droghe: controllo esteso a 9 nuove sostanze dal 18 settembre 2026
08 Mag
US FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
07 Mag
AIFA - Sistema informatico Workflow Officine Materie Prime - aggiornamento
30 Apr
AIFA pubblica il Terzo Position Paper sui farmaci biosimilari
29 Apr
US GDUFA IV Talks Reach Tentative Agreement; America First Application Fee Waiver Added
28 Apr
Sun Pharma compra Organon
27 Apr
US QMM: Participants scored well on commitment to quality, lower on advanced manufacturing